

DAFTAR PUSTAKA

1. Luo M-S, Huang G-J, Liu B-X. Immune infiltration in nasopharyngeal carcinoma based on gene expression. *Medicine*. 2019;98(39):1–7.
2. Cen RX, Li YG, Li Y. Platelet-to-lymphocyte ratio as a potential prognostic factor in nasopharyngeal carcinoma: A meta-analysis. *Medicine*. 2019;98(38):1–8.
3. Challapalli SD, Simpson MC, Adjei Boakye E, Walker RJ, Antisdell JL, Ward GM, et al. Survival differences in nasopharyngeal carcinoma among racial and ethnic minority groups in the United States: A retrospective cohort study. *Clin Otolaryngol*. 2019;44(1):14–20.
4. Wu SG, Zhang QH, Zhang WW, Sun JY, Lin Q, He ZY. The effect of marital status on nasopharyngeal carcinoma survival: A surveillance, epidemiology and end results study. *J Cancer*. 2018;9(10):1870–6.
5. Zhu Y, Song X, Li R, Quan H, Yan L. Assessment of Nasopharyngeal Cancer in Young Patients Aged ≤ 30 Years. *Frontiers Oncol*. 2019;9(1179):1–8.
6. Sun L, Song J, Huang Q. Clinicopathological and prognostic significance of p16 protein in nasopharynx cancer patients. *Medicine*. 2019;98(11):1–9.
7. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. *Chin J Cancer*. 2012;31(4):185–96.
8. Sofiani EG, Rahmawaty S. Tingkat Pengetahuan Gizi, Asupan Energi - Protein dan Status Gizi Pasien Kanker Nasofaring yang Mendapatkan Kemoterapi. *Darussalam Nutr J*. 2018;2(2):14–20.
9. World Health Organization. Indonesia Source GLOBOCAN 2018. *Int Agency Research Cancer*. 2019;256:1–2.
10. Wang K, Dong J, He S, Wang X, Jiang C, Hu P, et al. Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma. *BMC Cancer*. 2019;19(1):1–9.
11. Diniati A, Ade W, Harianto. Distribusi keganasan nasofaring berdasarkan pemeriksaan histopatologi pada rumah sakit di kota Pekanbaru tahun 2009–2013. *J Online Mhs Fk*. 2016;3(1):1–18.
12. Salehiniya H, Mohammadian M, Mohammadian-Hafshejani A, Mahdaviifar N. Nasopharyngeal cancer in the world: epidemiology, incidence, mortality and risk factors. *World Cancer Res J*. 2018;5(1):1–8.
13. Alotaibi AD, Ahmed HG, Elsbali AM. Nasopharyngeal cancer in Saudi Arabia: Epidemiology and possible risk factors. *J Oncol Sci*. 2019;5(1):23–30.
14. Cetindağ MF, Özsavran AY, Yalçın B, Çetindağ İ, Ercan K, Türkölmez Ş,

- et al. The results of nasopharyngeal cancer patients treated by simultaneous integrated boost technique and concomitant chemotherapy. *Turkish J Med Sci.* 2019;49(2):558–65.
15. Guo R, Mao Y-P, Tang L-L, Chen L, Sun Y, Ma J. The evolution of nasopharyngeal carcinoma staging. *British J Radiol.* 2019;92(1102):1–9.
 16. Wang HY, Li F, Liu N, Liu XY, Yang XH, Guo YM, et al. Prognostic implications of a molecular classifier derived from whole-exome sequencing in nasopharyngeal carcinoma. *Cancer Med.* 2019;8(6):2705–16.
 17. Guthrie GJK, Charles KA, Roxburgh CSD, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer. *Oncol Hematol.* 2013;88(1):218–30.
 18. Xie XC, Zeng XC, Cao SJ, Hu XM, Shi QJ, Li D, et al. Elevated pretreatment platelet distribution width and platelet count predict poor prognosis in nasopharyngeal carcinoma. *Oncotarget.* 2017;8(62):106089–97.
 19. Lu A, Li H, Zheng Y, Tang M, Li J, Wu H, et al. Prognostic Significance of Neutrophil to Lymphocyte Ratio, Lymphocyte to Monocyte Ratio, and Platelet to Lymphocyte Ratio in Patients with Nasopharyngeal Carcinoma. *Biomed Res Int.* 2017;2017(3047802):1–6.
 20. Plantureux L, Mège D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Impacts of cancer on platelet production, activation and education and mechanisms of cancer-associated thrombosis. *Cancers.* 2018;10(11):1–23.
 21. Wojtukiewicz MZ, Sierko E, Hempel D, Tucker SC, Honn K V. Platelets and cancer angiogenesis nexus. *Cancer Metastasis Rev.* 2017;36(2):249–62.
 22. Chen YP, Chen C, Mai ZY, Gao J, Shen LJ, Zhao BC, et al. Pretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients. *Oncol Letters.* 2015;9(3):1458–66.
 23. Gao J, Zhang HY, Xia YF. Increased platelet count is an indicator of metastasis in patients with nasopharyngeal carcinoma. *Tumor Biol.* 2013;34(1):39–45.
 24. Chen SS. *Carcinogenesis, Diagnosis, and Molecular Targeted treatment for Nasopharyngeal Carcinoma.* 1st ed. Croatia: InTech; 2012. p. 95–233.
 25. Cheesman K, Burdett E. *Anatomy of the nose and pharynx.* *Anaesth Intensive Care Med.* 2011;12(7):283–6.
 26. McKinley M, O’Loughlin V. *Human Anatomy.* 3rd ed. New York: McGraw-Hill companies; 2012. p. 752–754.
 27. Desen W. *Karsinoma Nasofaring.* In: *Buku Ajar Onkologi Klinis.* 2nd ed. Jakarta: Balai Penerbit FKUI; 2008. p. 267–8.
 28. Brandwein MS. *Textbook of head and neck pathology.* 1st ed. Switzerland: Springer International Publishing; 2016. p. 128–153.

29. Adams GL, Boies LR, Hilger PA. BOIES Buku Ajar Penyakit THT. 6th ed. Effendi H, editor. Jakarta: EGC; 1997. p. 280–281.
30. Lund VJ, Howard DJ, Wei WI. Tumors of The nose, Sinuses, and Nasopharynx. 1st ed. New York: Thieme Medical Publisher; 2014. p. 533–568.
31. Evans P, Montgomery paul q, Gullane PJ, Evans PHR. principles and practice of head and neck surgery and oncology. 2nd ed. London: Informa; 2009. p. 343–362.
32. Paulsen F, Waschke J. Sobotta Atlas Anatomi Manusia Jilid III. 23rd ed. Jakarta: EGC; 2012. p. 175–177.
33. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80.
34. Wang H-Y, Chang Y-L, To K-F, Hwang JSG, Mai H-Q, Feng Y-F, et al. A new prognostic histopathologic classification of nasopharyngeal carcinoma. Chin J Cancer. 2016;35(1):41.
35. Nair JKR, Vallières M, Mascarella MA, Sabbagh N El, Duchatellier CF, Zeitouni A, et al. Magnetic Resonance Imaging Texture Analysis Predicts Recurrence in Patients With Nasopharyngeal Carcinoma. Can Assoc Radiol J. 2019;70(4):394–402.
36. Dwijayanti F, Prabawa A, Besral, Herawati C. The Five-Year Survival Rate of Patients with Nasopharyngeal Carcinoma Based on Tumor Response after Receiving Neoadjuvant Chemotherapy, Followed by Chemoradiation, in Indonesia: A Retrospective Study. Oncology. 2020;98(3):154–60.
37. Xiao X, Zhang Z, Chang ET, Liu Z, Liu Q, Cai Y, et al. Medical History , Medication Use , and Risk of Nasopharyngeal Carcinoma. American J Epidemiol. 2018;187(10):2117–25.
38. Tsao SW, Tsang CM, Lo KW. *Epstein-barr virus* infection and nasopharyngeal carcinoma. Philosophical Trans Biol. 2017;372(1732):1–15.
39. Swain SK, Samal S, Anand N, Mohanty JN. Pediatric Nasopharyngeal Carcinoma. Int J Heal Allied Sci. 2019;9(1):1–6.
40. Soepardi EA, Iskandar N, Bashiruddin J, Restuti RD. Buku Ajar Ilmu Kesehatan Telinga Hidung Tenggorok Kepala Leher. 5th ed. Jakarta: Balai Penerbit FKUI; 2003. p. 146–150.
41. Zhou T, Yang DW, He YQ, Xue WQ, Liao Y, Zheng MQ, et al. Associations between environmental factors and serological *Epstein-Barr virus* antibodies in patients with nasopharyngeal carcinoma in South China. Cancer Med. 2019;8(10):4852–66.
42. Liu S-L, Sun X-S, Li X-Y, Tang L-Q, Chen Q-Y, Lin H-X, et al. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study. Cancer Commun. 2019;39(1):1–14.

43. Wu L, Li C, Pan L. Nasopharyngeal carcinoma: A review of current updates. *Exp Ther Med.* 2018;15(4):3687–92.
44. Feng R-M, Chang ET, Liu Z, Liu Q, Cai Y, Zhang Z, et al. Reproductive history and risk of nasopharyngeal carcinoma: A population-based case–control study in southern China. *Oral Oncol.* 2019;88(1):102–8.
45. Huang H-C, Tantoh DM, Hsu S-Y, Nfor ON, Frank C-FL, Lung C-C, et al. Association between coarse particulate matter (PM 10-2.5) and nasopharyngeal carcinoma among Taiwanese men. *J Investig Med.* 2020;68(2):419–24.
46. Yong SK, Ha TC, Yeo MCR, Gaborieau V, McKay JD, Wee J. Associations of lifestyle and diet with the risk of nasopharyngeal carcinoma in Singapore: a case–control study. *Chin J Cancer.* 2017;36(1):1–8.
47. Mai ZM, Lo CM, Xu J, Chan KP, Wong CM, Lung ML, et al. Milk consumption in relation to incidence of nasopharyngeal carcinoma in 48 countries/regions. *BMC Cancer.* 2015;15(1):1–15.
48. Jia W-H, Qin H-D. Non-viral environmental risk factors for nasopharyngeal carcinoma: A systematic review. *Seminars Cancer Biol.* 2012;22(2):117–26.
49. Young LS, Dawson CW. *Epstein-Barr Virus* and nasopharyngeal carcinoma. *Chin J Cancer.* 2014;33(12):581–90.
50. Dawson CW, Port RJ, Young LS. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). *Seminars Cancer Biol.* 2012;22(2):144–53.
51. Huang S, Tsao S, Tsang C. Interplay of Viral Infection, Host Cell Factors and Tumor Microenvironment in the Pathogenesis of Nasopharyngeal Carcinoma. *Cancers.* 2018;10(4):106–23.
52. Gourzones C, Busson P, Raab-Traub N. *Epstein-Barr Virus* and The Pathogenesis of Nasopharyngeal Carcinoma. In: *Nasopharyngeal Carcinoma keys for Translational Medicine and Biology.* 1st ed. new york: Springer Science; 2013. p. 52–4.
53. Hao S-P, Tsang N-M. Nasopharyngeal Carcinoma. In: *Practical Head and Neck Oncology.* 1st ed. san diego: Plural Publishing inc; 2009. p. 175–84.
54. Primadina MA, Imanto M. Tumor Nasofaring dengan Diplopia Pada Pasien Usia 44 Tahun. *J Medula.* 2017;7(4):181–6.
55. Khoo AS-B, Pua K-C. Diagnosis and Clinical Evaluation of Nasopharyngeal Carcinoma. In: *Nasopharyngeal Carcinoma keys for Translational Medicine and Biology.* 1st ed. New York: Springer Science+Business Media; 2013. p. 2–6.
56. Watkinson JC, Gilbert RW. *Stell & Maran’s Textbook of Head and Neck Surgery and Oncology.* 5th ed. London: Hodder Arnold; 2012. p. 590–595.
57. Pastor M, Lopez Pousa A, del Barco E, Perez Segura P, Astorga BG, Castelo

- B, et al. SEOM clinical guideline in nasopharynx cancer (2017). *Clin Transl Oncol*. 2018;20(1):84–8.
58. Arslan N, Tuzuner A, Koyucu A, Dursun S, Hucumenoglu S. The role of nasopharyngeal examination and biopsy in the diagnosis of malignant diseases. *Brazilian J Otorhinolaryngol*. 2019;85(4):481–5.
 59. American Joint Committee on Cancer. AJCC Cancer Staging Form Supplement eighth edition. *Am Coll Surg*. 2018;17–20.
 60. Mai H-Q, Zhang, Chen, Liu, Tang. Emerging treatment options for nasopharyngeal carcinoma. *Drug Design Development Ther*. 2013;7(1):37–52.
 61. Lee VH, Lam K-O, Chang AT, Lam T-C, Chiang C-L, So T-H, et al. Management of Nasopharyngeal Carcinoma: Is Adjuvant Therapy Needed? *J Oncol Pract*. 2018;14(10):594–602.
 62. Yoshizaki T, Ito M, Muroso S, Wakisaka N, Kondo S, Endo K. Current understanding and management of nasopharyngeal carcinoma. *Auris Nasus Larynx*. 2012;39(2):137–44.
 63. Kaushansky K, Lichtman MA, Prchal JT, Beutler E, Kipps TJ, Seligsohn U. *Williams Hematology*. 8th ed. New York: The McGraw-Hill Companies; 2010. p. 113–136.
 64. Paniccia R, Priora R, Alessandrello Liotta A, Abbate R. Platelet function tests: a comparative review. *Vasc Health Risk Manag*. 2015;11(1):133–48.
 65. Guyton AC, Hall JE. *Guyton and Hall Text Book of Medical Physiology*. 11th ed. Philadelphia: Elsevier inc; 2006. p. 457–459.
 66. Haemmerle M, Stone RL, Menter DG, Afshar-Khargan V, Sood AK. The Platelet Lifeline to Cancer: Challenges and Opportunities. *Cancer Cell*. 2018;176(10):965–83.
 67. Chen YP, Zhao BC, Chen C, Shen LJ, Gao J, Mai ZY, et al. Pretreatment platelet count improves the prognostic performance of the TNM staging system and aids in planning therapeutic regimens for nasopharyngeal carcinoma: A single-institutional study of 2,626 patients. *Chin J Cancer*. 2015;34(3):1–10.
 68. Yenita, Asri A. Korelasi antara Latent Membrane Protein-1 Virus Epstein-Barr dengan P53 pada Karsinoma Nasofaring (Penelitian Lanjutan). *J Kesehat Andalas*. 2012;1(1):4–6.
 69. Faiza S, Rahman S, Asri A. Karakteristik Klinis dan Patologis Karsinoma Nasofaring di Bagian THT-KL RSUP Dr.M.Djamil Padang. *J Kesehat Andalas*. 2016;5(1):90–6.
 70. Wang K. Nasopharyngeal Carcinoma Diagnostic Challenge in a Nonendemic Setting: Our Experience with 101 Patients. *Permanente J*. 2017;21(1):1–5.

71. Xie S, Yu IT, Tse L, Mang OW, Yue L. Sex difference in the incidence of nasopharyngeal carcinoma in Hong Kong 1983 – 2008 : Suggestion of a potential protective role of oestrogen. *Eur J Cancer*. 2013;49(1):150–5.
72. Xiao G, Cao Y, Qiu X, Wang W, Wang Y. Influence of gender and age on the survival of patients with nasopharyngeal carcinoma. *BMC Cancer*. 2013;13(226):1–8.
73. Pradiptha IPY, Nuaba IGA. Profil pasien karsinoma nasofaring dengan anemia yang dirawat di RSUP Sanglah Denpasar periode Januari 2017-Desember 2018. *Medicina (B Aires)*. 2019;50(2):277–80.
74. Mentari S, Imanto M. Kualitas Hidup Pasien Karsinoma Nasofaring : Review Naratif Health-Related Quality of Life in Nasopharyngeal Carcinoma Patient : A Narrative Review. *Med J LAMPUNG Univ*. 2019;8(2):227–33.
75. Sudoyo AW, Rachman A, Harimurti K. Angiogenesis, inflammation, platelets count, and metastatic status as a predictor for thrombosis risk in nasopharyngeal carcinoma patients. *Acta Med Indones*. 2015;47(1):11–5.
76. Lin Y-H, Chang K-P, Lin Y-S, Chang T-S. Pretreatment combination of platelet counts and neutrophil – lymphocyte ratio predicts survival of nasopharyngeal cancer patients receiving intensity-modulated radiotherapy. *Onco Targets Ther*. 2017;10(1):2751–60.

